CAPItello-291

Approved by EMA, novel oral AKT inhibitor in combination improves clinical outcomes and prolongs quality of life in patients with advanced HR+/HER2- breast cancer

Based on results from the CAPITello-291 phase III study, co-led by VHIO’s Mafalda Oliveira, Senior Medical Oncologist at Vall d’Hebron…

Novel AKT inhibitor combined with standard hormone therapy shows promise for patients with pre-treated metastatic HR+/ HER2- breast cancer

Approximately 70% of advanced breast cancers are hormone receptor-positive (HR+)/HER2-negative. Hormone therapies are widely used for the treatment of patients…